Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:AVTXNASDAQ:CNTBNASDAQ:FREQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.88-2.3%$1.70$1.21▼$3.81$46.43M0.68259,353 shs88,995 shsAVTXAvalo Therapeutics$3.75-4.1%$5.41$3.39▼$16.00$40.61M0.8753,951 shs29,521 shsCNTBConnect Biopharma$0.76-8.4%$0.74$0.51▼$2.07$41.79M-0.356,257 shs84,790 shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-2.34%+11.90%+22.08%-32.62%-2.59%AVTXAvalo Therapeutics-4.09%-4.09%-24.24%-55.57%-65.25%CNTBConnect Biopharma-8.37%+0.53%+11.03%-13.23%-55.59%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi BioscienceN/AN/AN/AN/AN/AN/AN/AN/AAVTXAvalo Therapeutics3.3892 of 5 stars4.45.00.00.00.01.71.3CNTBConnect Biopharma2.7417 of 5 stars3.55.00.00.00.62.50.6FREQFrequency TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-11.35% DownsideAVTXAvalo Therapeutics 2.83Moderate Buy$33.00780.00% UpsideCNTBConnect Biopharma 3.00Buy$8.00959.60% UpsideFREQFrequency Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FREQ, CNTB, AVTX, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.002/28/2025AVTXAvalo TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.85N/AN/A$4.29 per share0.44AVTXAvalo Therapeutics$441K92.07N/AN/A$9.11 per share0.41CNTBConnect Biopharma$26.03M1.61N/AN/A$1.83 per share0.41FREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)AVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)CNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AFREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/ALatest FREQ, CNTB, AVTX, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A3/18/2025Q4 2024AADIAadi Bioscience-$0.30-$0.67-$0.37-$0.67$7.45 million$7.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AFREQFrequency TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54AVTXAvalo TherapeuticsN/A1.421.42CNTBConnect BiopharmaN/A12.04N/AFREQFrequency TherapeuticsN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%AVTXAvalo Therapeutics87.06%CNTBConnect Biopharma58.72%FREQFrequency Therapeutics13.18%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%AVTXAvalo Therapeutics3.03%CNTBConnect Biopharma22.60%FREQFrequency Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableFREQ, CNTB, AVTX, and AADI HeadlinesRecent News About These CompaniesMolecular Response to Therapy Linked With Event-Free Survival in PVMay 23 at 9:55 PM | ajmc.comIn uncertain times, focus on the mission, Cognito Therapeutics leaders sayApril 16, 2025 | medicaldesignandoutsourcing.comTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comProgentos Therapeutics CEO Chris Loose named board member and chair of the Fellowship and Programs Council for Hertz FoundationFebruary 27, 2025 | eurekalert.orgKRRO stock touches 52-week low at $29.8 amid yearly slumpFebruary 11, 2025 | msn.compay n play casino trustlyDecember 29, 2024 | bwdisrupt.businessworld.inSilence Therapeutics Advances Promising siRNA Therapy for PVDecember 10, 2024 | markets.businessinsider.comFrequency Exchange and gethealthy.store Launch "Nikki" Wellness Technology Into 1,000+ Clinic StoresDecember 5, 2024 | finance.yahoo.comFrequency Exchange Welcomes Former NHL Star and Current President of the Boston Bruins Cam Neely to Its Advisory BoardNovember 22, 2024 | finance.yahoo.comCognito Therapeutics highlights cost-effectiveness of neuromod for Alzheimer’sNovember 20, 2024 | massdevice.comLeamington hospital launches revolutionary robotic prostate treatment therapy for menNovember 14, 2024 | msn.comPromising Developments at Astria Therapeutics Bolster Buy RecommendationNovember 14, 2024 | markets.businessinsider.comStudy finds Tetris-based therapy can ease post-traumatic stress disorder symptomsNovember 14, 2024 | msn.com‘Most depressing, low-energy, low-frequency city:’ Kolkata India’s ‘dirtiest city’ says X user, triggering heated debate onlineNovember 7, 2024 | timesofindia.indiatimes.comRapport Therapeutics Reports Third Quarter Financials and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comModulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinomaNovember 5, 2024 | news-medical.netTherapy using a digital avatar could help patients suffering from psychosis, study saysNovember 4, 2024 | msn.comTG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue GuidanceNovember 4, 2024 | markets.businessinsider.comNew research upends long-held beliefs about romantic love and sexual frequencyNovember 4, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFREQ, CNTB, AVTX, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.88 -0.05 (-2.34%) As of 05/22/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Avalo Therapeutics NASDAQ:AVTX$3.75 -0.16 (-4.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.94 +0.19 (+5.07%) As of 05/23/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Connect Biopharma NASDAQ:CNTB$0.76 -0.07 (-8.37%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$0.77 +0.02 (+1.99%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Frequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
